For Hashimotos patients who are dealing with insulin resistance and constant hunger, glucomannan can be a game-changer
Alberti KGMM, Zimmet P, Shaw J
It also reflects strong work across peptide stability, drug-device compatibility, analytical comparability, manufacturing readiness, and regulatory strategy
Phase 3 clinical trials collectively referred to as the TRIUMPH programme are now underway internationally, evaluating retatrutide across broader populations including individuals with type 2 diabetes, obesity-related cardiovascular disease, and metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH)
We acknowledge that obesity is a complex condition that requires personalized care and ongoing support